Andrew Ko, MD
Professor of Clinical Medicine; Interim Division Chief, Oncology, Division of Hematology/Oncology, UCSF
Cancer Center Program Memberships
Experimental TherapeuticsResearch Summary
My primary clinical and research interests focus on gastrointestinal malignancies, where I have developed and led multiple clinical trials, both within UCSF and across multiple sites nationwide and overseas. I am interested in the development and evaluation of new therapeutic agents ranging from novel cytotoxics to molecular targeted agents to immunotherapies, with a particular emphasis on evaluating these in patients with pancreatic cancer. This work has entailed collaborating with laboratory-based investigators on the correlative/translational science to identify individual patient/tumor characteristics that influence prognosis and response to specific therapies, including both tissue- and blood-based biomarkers. Other university responsibilities include leading the site committee for gastrointestinal cancer-specific clinical trial development at the UCSF HDFCCC and serving as chair of the scientific Protocol Review Committee. Nationally, I have served on the scientific program committee, grants committee, and specialty editorial board for the American Society of Clinical Oncology (ASCO), sit on the editorial board for multiple peer-reviewed oncology journals, and am currently a member of NCI’s Pancreatic Cancer Task Force and the NCCN Pancreatic Cancer guidelines committee.Education
Brown University, Providence, RI, Sc.B., 1991, Applied Mathematics/Biology
Johns Hopkins School of Medicine, Baltimore, MD, M.D., 1995, Medicine
Board certified, Internal Medicine, 1998
Board certified, Medical Oncology, 2002
Professional Experience
-
1995-1996
Beth Israel Hospital (Boston, MA), intern, Department of Internal Medicine -
1996-1998
Beth Israel Hospital (Boston, MA), resident, Department of Internal Medicine -
1998-2001
Stanford University School of Medicine, fellow, Division of Medical Oncology -
2001-present
University of California at San Francisco, Clinical Instructor, Division of Hematology/Oncology -
2003-2009
University of California at San Francisco, Assistant Clinical Professor, Division of Hematology/Oncology -
2009-2018
University of California at San Francisco, Associate Professor of Clinical Medicine, Division of Hematology/ Oncology -
2019-present
University of California, San Francisco, Professor of Clinical Medicine, Division of Hematology/Oncology -
2019-present
University of California, San Francisco, Interim Division Chief, Oncology, Division of Hematology/Oncology
Honors & Awards
- 1987
National Merit Scholarship - 1988
IBM Thomas J. Watson Memorial Scholarship - 1990
Sigma Xi, elected associate member - 1991
Departmental honors and Magna cum laude, Brown University - 1993
Alpha Omega Alpha, student essay competition honoree - 1994
Harry C. Saltzstein Prize in Medical Writing, Johns Hopkins School of Medicine - 1995
Medical Assistance Programs/Reader's Digest International Fellowship - 2000
Amgen National Oncology Fellows' Forum, selected for oral presentation - 2000
American Society of Clinical Oncology, Travel Award (meritorious abstract) - 2001
Digestive Disease Center Collaborative Postdoctoral Fellowship - 2003
UCSF Cancer Center Clinical Investigator Research Program award - 2003
American Society of Clinical Oncology Career Development Award - 2007
Joan Rombauer UCSF Endowed Fellowship - 2008
UCSF Kaiser Award for Excellence in Teaching in the Classroom Setting, nominee - 2011
NCI Cancer Clinical Investigator Team Leadership Award - 2013
UCSF Hematology and Oncology Division Teaching Award
Selected Publications
- Johns C, Diaz CL, Hwang J, Kerridge WD, Ko AH, Tempero MA. Alternate Week Gemcitabine and Capecitabine: An Effective Treatment for Patients With Pancreatic Adenocarcinoma. Pancreas. 2019 Jul 01.
View on PubMed - Ko AH, Nakakura EK. Adjuvant Therapy for Ampullary Cancer. JAMA Surg. 2019 May 29.
View on PubMed - Le DT, Picozzi VJ, Ko AH, Wainberg ZA, Kindler H, Wang-Gillam A, Oberstein P, Morse MA, Zeh HJ, Weekes C, Reid T, Borazanci E, Crocenzi T, LoConte NK, Musher B, Laheru D, Murphy A, Whiting C, Nair N, Enstrom A, Ferber S, Brockstedt DG, Jaffee EM. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study). Clin Cancer Res. 2019 May 24.
View on PubMed - Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, Bahary N, Bekaii-Saab T, Bali MA, Besselink MG, Boone BA, Chau I, Clarke S, Dillhoff M, El-Rayes BF, Frakes JM, Grose D, Hosein PJ, Jamieson NB, Javed AA, Khan K, Kim KP, Kim SC, Kim SS, Ko AH, Lacy J, Margonis GA, McCarter MD, McKay CJ, Mellon EA, Moorcraft SY, Okada KI, Paniccia A, Parikh PJ, Peters NA, Rabl H, Samra J, Tinchon C, van Tienhoven G, van Veldhuisen E, Wang-Gillam A, Weiss MJ, Wilmink JW, Yamaue H, Homs MYV, van Eijck CHJ, Katz MHG, Koerkamp BG. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. J Natl Cancer Inst. 2019 May 14.
View on PubMed - Walker EJ, Carnevale J, Pedley C, Blanco A, Chan S, Collisson EA, Tempero MA, Ko AH. Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma. Fam Cancer. 2019 Apr; 18(2):241-251.
View on PubMed - Kim SS, Ko AH, Nakakura EK, Wang ZJ, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Kim GE. Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stratification Be Favorable Toward Standardization? Am J Surg Pathol. 2019 Mar; 43(3):334-340.
View on PubMed - Tempero MA, Malafa MP, Chiorean EG, Czito B, Scaife C, Narang AK, Fountzilas C, Wolpin BM, Al-Hawary M, Asbun H, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chung V, Dillhoff M, Dotan E, Ferrone CR, Fisher G, Hardacre J, Hawkins WG, Ko AH, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Thayer S, Wolff RA, Burns JL, Zuccarino-Catania G. Pancreatic Adenocarcinoma, Version 1.2019. J Natl Compr Canc Netw. 2019 Mar 01; 17(3):202-210.
View on PubMed - Houston B, Thompson M, Ko A, Chizeck H. A machine-learning approach to volitional control of a closed-loop deep brain stimulation system. J Neural Eng. 2019 Feb; 16(1):016004.
View on PubMed - Munigala S, Gardner TB, O'Reilly EM, Castillo CF, Ko AH, Pleskow D, Mills JB, Vollmer CM, Searle NA, Alsante M, Holt JM, Gelrud A. Understanding Pancreatic Diseases Using Animated Pancreas Patient: Informing Patients for Better Health Outcomes With Visual Formats of Learning. Pancreas. 2018 Nov/Dec; 47(10):1256-1261.
View on PubMed - Ko AH. Moving from late to early stage disease: lessons learned from erlotinib in pancreatic cancer. Hepatobiliary Surg Nutr. 2018 Oct; 7(5):406-408.
View on PubMed - Wang ZJ, Behr S, Consunji MV, Yeh BM, Ohliger MA, Gao K, Ko AH, Cinar P, Tempero MA, Collisson EA. Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI. AJR Am J Roentgenol. 2018 Nov; 211(5):1010-1019.
View on PubMed - Savoie MB, Paciorek A, Zhang L, Van Blarigan EL, Sommovilla N, Abrams D, Atreya CE, Bergsland EK, Chern H, Kelley RK, Ko A, Laffan A, Sarin A, Varma MG, Venook AP, Van Loon K. Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment Initiation. J Gastrointest Cancer. 2018 Jul 30.
View on PubMed - Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018 May 10; 4(5):e180013.
View on PubMed - Ko AH. Shifting the treatment model for resectable pancreatic cancer. Lancet Gastroenterol Hepatol. 2018 06; 3(6):375-376.
View on PubMed - Heymach J, Krilov L, Alberg A, Baxter N, Chang SM, Corcoran RB, Dale W, DeMichele A, Magid Diefenbach CS, Dreicer R, Epstein AS, Gillison ML, Graham DL, Jones J, Ko AH, Lopez AM, Maki RG, Rodriguez-Galindo C, Schilsky RL, Sznol M, Westin SN, Burstein H. Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2018 04 01; 36(10):1020-1044.
View on PubMed - Ko AH. Clinical Management: Metastatic Disease. Cancer J. 2017 Nov/Dec; 23(6):355-361.
View on PubMed - Ko AH, Murphy PB, Peyton JD, Shipley DL, Al-Hazzouri A, Rodriguez FA, Womack MS, Xiong HQ, Waterhouse DM, Tempero MA, Guo S, Lane CM, Earwood C, DeBusk LM, Bendell JC. A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial. Oncologist. 2017 12; 22(12):1427-e129.
View on PubMed - Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chiorean EG, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Hardacre J, Hawkins WG, Herman J, Ko AH, Komanduri S, Koong A, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Scaife C, Thayer S, Weekes CD, Wolff RA, Wolpin BM, Burns J, Darlow S. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 08; 15(8):1028-1061.
View on PubMed - Greene C, Nakakura EK, Ko AH. Gastrocutaneous Fistula in a Patient with Locally Recurrent MSI-High Colorectal Cancer: Local Complications Arising from Therapeutic Response to Immune Checkpoint Blockade. Anticancer Res. 2017 07; 37(7):3679-3684.
View on PubMed - Lieu CH, Hidalgo M, Berlin JD, Ko AH, Cervantes A, LoRusso P, Gerber DE, Eder JP, Eckhardt SG, Kapp AV, Tsuhako A, McCall B, Pirzkall A, Uyei A, Tabernero J. A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS. Oncologist. 2017 09; 22(9):1024-e89.
View on PubMed